Last reviewed · How we verify
Glossopharyngeal neuralgia
Approved treatments
- Tegretol · Novartis AG (originally Geigy)
Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain. - Carbamazepin · Enanta Pharmaceuticals, Inc
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Glossopharyngeal neuralgia patent landscape — cliff calendar, originator estates, attackable patents
- Glossopharyngeal neuralgia treatment landscape brief
- Glossopharyngeal neuralgia treatment updates RSS
Frequently asked questions about Glossopharyngeal neuralgia
What drugs treat Glossopharyngeal neuralgia?
Tracked treatments include Tegretol, Carbamazepin.
What is the treatment for Glossopharyngeal neuralgia?
Standard treatment for Glossopharyngeal neuralgia includes Tegretol, Carbamazepin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Glossopharyngeal neuralgia patent cliff · Glossopharyngeal neuralgia CI report
- Treatment: Tegretol · Novartis AG (originally Geigy)
- Treatment: Carbamazepin · Enanta Pharmaceuticals, Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing